Group 1 - Haisun Pharmaceutical's stock price dropped by 5.07% to 7.87 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.36%, resulting in a total market capitalization of 12.739 billion CNY [1] - The company, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province, and specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The revenue composition of Haisun Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, a fund under Southern Fund holds a significant position, with the Southern CSI 1000 ETF (512100) reducing its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 4.3505 million CNY [2] - The Southern CSI 1000 ETF was established on September 29, 2016, with a current scale of 78.996 billion CNY, yielding a return of 9.47% this year, ranking 1524 out of 5569 in its category, and a one-year return of 34.09%, ranking 1864 out of 4295 [2]

Core Viewpoint - Haishang Pharmaceutical (002099) has introduced the "innovative drug" concept based on its R&D strategy and past performance, while also announcing abnormal stock trading fluctuations due to significant price changes over three consecutive trading days [1] Stock Performance - The stock price has shown significant volatility in the past week, with a closing price of 7.51 yuan on February 6, reaching a peak of 8.26 yuan on February 9, and closing at 8.38 yuan on February 10, resulting in a cumulative increase of 23.13% over five days and 34.78% year-to-date [2] - As of February 12, the latest price was 8.41 yuan, with a daily fluctuation of 6.71% and a turnover rate of 5.09%, indicating a net outflow of 48.41 million yuan from major funds on that day [2] - The top five buyers on February 10 were primarily from the Shenzhen Stock Connect and institutional investors, reflecting increased capital attention [2] Financial Report Analysis - The company expects a net loss attributable to shareholders of 90 million to 135 million yuan for 2025, marking a narrowing of losses compared to 2024, but continuing a three-year trend of losses primarily due to pressure on the pharmaceutical segment and a decline in the dye business [3] - Revenue for the first three quarters of 2025 is projected at 1.367 billion yuan, a year-on-year decrease of 5.39%, although there is a quarter-on-quarter improvement [3] - Some institutions predict a potential turnaround in net profit to 367 million yuan for 2025, but caution is advised based on a minority of institutional views [3] Institutional Perspectives - Market sentiment is generally neutral, with low frequency of institutional research and no significant changes in ratings [4] - The recent price surge in dyes may enhance profit elasticity, but the company still faces dual business pressures, and investments in innovative drugs carry high risks [4]

Group 1 - The company, Haixiang Pharmaceutical, announced a stock price fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days on February 6, 9, and 10, 2026 [1] - The company confirmed that there is no need to correct or supplement previously disclosed information, and its operational status remains normal without significant changes in the internal or external environment [1] - The controlling shareholder and actual controller have not engaged in any undisclosed significant matters or traded the company's stock during the fluctuation period [1] Group 2 - As of February 10, 2026, the company has repurchased a total of 14,315,300 shares, accounting for 0.8844% of the total share capital, with a total transaction amount of 88,881,298.38 yuan [1] - The partnership firm has converted its unlisted shares of Fuhong Hanlin into H-shares, which were listed on the Hong Kong Stock Exchange on February 4, 2026 [1] - There are no revisions to the earnings forecast for the fiscal year 2025 [1]

Core Viewpoint - The stock of Haixiang Pharmaceutical experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% over three consecutive trading days from February 6 to February 10, 2026 [1] Group 1: Stock Performance - The company confirmed that there were no significant changes in its operational environment and that its business operations remain normal [1] - The controlling shareholder and actual controller did not engage in any buying or selling of the company's shares during the period of stock fluctuation [1] Group 2: Share Buyback - The company approved a share repurchase plan on April 9, 2025, and as of February 10, 2026, it has repurchased a total of 14,315,300 shares, accounting for 0.8844% of the total share capital, with a total transaction amount of 88,881,298.38 yuan [1] Group 3: Investment and Market Activity - The partnership in which the company invested completed the conversion of its unlisted shares of Fuhong Hanlin on February 4, 2026, and these shares have been listed on the Hong Kong Stock Exchange [1] - The company confirmed that there are no undisclosed significant matters that could impact its stock price [1]

Group 1 - The company's stock experienced an abnormal fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days on February 6, 9, and 10, 2026 [1] - As of February 10, the company has repurchased a total of 14.3153 million shares, accounting for 0.8844% of the total share capital, with a transaction amount of 88.8813 million yuan [1] - The company’s investment partnership completed the transfer of unlisted shares of Fuhong Hanlin to H-shares, which were listed on the Hong Kong Stock Exchange on February 4 [1] Group 2 - The company projects a net profit for the fiscal year 2025 to be between -135 million yuan and -90 million yuan, with a non-recurring net profit expected to be between -142 million yuan and -95 million yuan [1]

证券代码：002099 证券简称：海翔药业 公告编号：2026-009 浙江海翔药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 浙江海翔药业股份有限公司（以下简称"公司"）股票（证券简称：海翔药 业，证券代码：002099）于2026年2月6日、2026年2月9日、2026年2月10日连续3 个交易日收盘价格涨幅偏离值累计超过了20%，根据深圳证券交易所（以下简称 "深交所"）的有关规定，属于股票交易异常波动的情况。 二、关注、核实情况说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并向公司控股股 东及实际控制人、公司董事、高级管理人员进行核实，现将有关情况说明如下： 6、公司参投的合伙企业持有复宏汉霖境内未上市股份已于2026年2月4日完 成转换为H股，并已在香港联交所上市。具体内容详见公司于2026年2月6日在《证 券时报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于参 投合伙企业投资复宏汉霖的进展公告》（公告编号：2026-008）。 ...

Group 1 - The A-share innovative drug sector is experiencing significant fluctuations and has become a core highlight in the pharmaceutical industry, with companies like Wanbangde and Haixiang Pharmaceutical hitting the daily limit up [1] - Multiple stocks, including Xinlitai and Hansen Pharmaceutical, are rising in tandem, indicating a dual-leader effect and a broader market rally within the sector [1] - Increased market attention and net capital inflow are evident, showcasing a clear upward trend and structural opportunities within the sector [1] Group 2 - A major strategic partnership has been established between Innovent Biologics and Eli Lilly, enhancing confidence in the sector and promoting the globalization of domestic innovative drugs [2] - The industry is projected to experience strong growth, with a significant increase in the number of approved domestic innovative drugs and market size by 2025, alongside record-high overseas licensing transactions [2] - Continuous policy support is evident, with the 2025 version of the medical insurance catalog adding several innovative drugs, addressing implementation challenges and providing a supportive framework for industry development [2] Group 3 - The innovative drug research and development sector is a core beneficiary of policy, technology, and globalization benefits, with companies like Wanbangde and Xinlitai directly benefiting from the industry's growth [3] - The pharmaceutical raw materials and CDMO sectors, represented by Haixiang Pharmaceutical, are also benefiting from the commercialization of innovative drugs, leading to increased demand [3] - The traditional Chinese medicine innovative drug sector is experiencing growth due to industry innovation and policy support, with companies like Hansen Pharmaceutical and Qianjin Pharmaceutical participating in the sector's upward trend [3]

Core Viewpoint - Haisheng Pharmaceutical (SZ002099) experienced a limit-up on February 10, 2026, reaching a price of 9.09 yuan, with a 10.05% increase, and a total market capitalization of 14.714 billion yuan [1] Group 1: Company Developments - The stock price surge is attributed to advancements in innovative drug development, with products NWRD06 and NWRD08 entering Phase II clinical trials, and WP205 receiving FDA orphan drug designation, enhancing market competitiveness [2] - The rapid recovery of the dye segment has significantly contributed to the stock price increase, with core product prices rising and profitability improving, thereby reducing goodwill impairment risks and enhancing financial performance [2] - The company is actively pursuing strategic collaborations, including partnerships with the University of Science and Technology of China and Wanbangde to develop drugs for ALS, which expands its R&D capabilities and business scope [2] Group 2: Market and Technical Analysis - The pharmaceutical sector has become a market hotspot due to the progress in innovative drug development and supportive industry policies, leading to positive performances from related stocks [2] - Data from Tonghuashun indicates a net inflow of large orders on the day, suggesting that major funds are optimistic about the company's future prospects [2] - The MACD indicator for the stock has formed a golden cross recently, indicating an increase in short-term upward momentum [2]

Group 1 - The stock of Haixiang Pharmaceutical has achieved a three-day limit-up, indicating strong market interest and performance [1] - The stock reached a trading limit at 10:11 AM with a transaction volume of 1.309 billion yuan and a turnover rate of 9.44% [1] - The company operates in the pharmaceutical and dye industries, with a fully integrated production chain for its main products [1] Group 2 - In the dye sector, Haixiang's leading products, such as the active blue KN-R series, have been recognized with the National Manufacturing Single Champion title [1] - In the innovative drug sector, the company has invested in multiple projects, including vaccines for HPV infection and liver cancer, with some projects already in clinical stages [1] - In the active pharmaceutical ingredient sector, Haixiang leads global market share with products like clindamycin and meropenem, maintaining long-term collaborations with major pharmaceutical companies like Pfizer and BI [1]

Group 1: Price Adjustments - Zhejiang Longsheng announced a price increase of 5000 yuan/ton for certain disperse dye products due to rising prices of reducing agents [1] - Lun土股份 also reported a similar price increase of approximately 5000 yuan/ton for disperse black dye, attributing it to the rising costs of reducing agents [1] - Fulaient has issued a price adjustment notice for multiple disperse dye products, with increases ranging from 2000 to 3000 yuan per ton, expected to be around 10% [1] Group 2: Industry Overview - The disperse dye sector has seen a recent surge, with companies like Haixiang Pharmaceutical and Jihua Group experiencing significant stock performance [2] - China is the largest producer, trader, and consumer of dyes globally, accounting for approximately 70%-75% of the world's total dye production [2] - Major production areas for dyes in China include Zhejiang, Jiangsu, and Shandong, with a high industry concentration [2] Group 3: Market Trends - The disperse dye industry has faced a downward trend over the past five years, but a turning point is emerging as the core intermediate, reducing agents, has started to increase in price [3] - The price of reducing agents rose over 50% from 25,000 yuan/ton to 38,000 yuan/ton by the end of January [3] - Disperse dye prices have also been on the rise, with increases noted in January, indicating a potential price turning point [3] Group 4: Future Outlook - The production of reducing agents is subject to high environmental standards and complex processes, leading to the exit of smaller producers unable to meet these standards [4] - The supply structure is highly concentrated, with major capacities held by integrated giants, which may lead to sustained price increases for reducing agents [4] - The traditional peak season for the printing and dyeing industry in March and April may exacerbate supply-demand tensions as downstream manufacturers stock up in anticipation of price hikes [4]